TG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Tara Bancroft - TD Cowen Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B.
TG Therapeutics (TGTX) Lags Q3 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.73 per share a year ago.
TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.34 per share a year ago.
TG Therapeutics: Pressure On Briumvi To Perform As Share Price Hits Resistance
Shares of TG Therapeutics had a volatile journey in the last 12 months and have hit resistance levels in the low 20s again. I expect the company to report strong sequential growth of Briumvi, but with less room for significant increases in the full-year guidance after a large increase in May. New patient starts should exceed 1,400 in the second quarter, and we should hear management comments on how they are preparing for the launch of subcutaneous Ocrevus in Q4.
